IQVIA Holdings Inc. $IQV Stock Position Decreased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 223,725 shares of the medical research company’s stock after selling 21,374 shares during the period. Assenagon Asset Management S.A. owned about 0.13% of IQVIA worth $50,430,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC grew its stake in IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in IQVIA in the second quarter worth $514,000. Charles Schwab Investment Management Inc. lifted its stake in IQVIA by 1.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 1,261,383 shares of the medical research company’s stock valued at $198,781,000 after buying an additional 13,163 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its stake in IQVIA by 3.2% in the second quarter. Coldstream Capital Management Inc. now owns 3,378 shares of the medical research company’s stock valued at $532,000 after buying an additional 106 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IQV shares. Morgan Stanley set a $240.00 price target on shares of IQVIA in a research report on Wednesday, February 11th. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research report on Friday, March 6th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Truist Financial dropped their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Finally, Evercore reaffirmed an “outperform” rating and set a $225.00 price target on shares of IQVIA in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $229.13.

IQVIA Stock Down 0.5%

IQV stock opened at $166.19 on Wednesday. The firm has a market cap of $28.20 billion, a PE ratio of 21.14, a P/E/G ratio of 1.61 and a beta of 1.39. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a 50 day simple moving average of $191.14 and a 200 day simple moving average of $205.92.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter in the prior year, the company earned $3.12 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.